PACK Private Wealth LLC Takes $203,000 Position in Eli Lilly and Company (NYSE:LLY)

PACK Private Wealth LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 224 shares of the company’s stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. AMJ Financial Wealth Management bought a new stake in Eli Lilly and Company during the fourth quarter worth $201,000. Providence First Trust Co bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $274,000. Aveo Capital Partners LLC boosted its holdings in shares of Eli Lilly and Company by 8.2% in the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after buying an additional 153 shares during the last quarter. Gryphon Financial Partners LLC grew its position in Eli Lilly and Company by 19.4% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after buying an additional 377 shares during the period. Finally, Bogart Wealth LLC increased its holdings in Eli Lilly and Company by 61.5% during the fourth quarter. Bogart Wealth LLC now owns 289 shares of the company’s stock worth $168,000 after buying an additional 110 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 1.1 %

Eli Lilly and Company stock opened at $946.31 on Thursday. The stock has a market cap of $899.38 billion, a P/E ratio of 139.37, a PEG ratio of 2.91 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The firm’s fifty day moving average price is $895.96 and its 200-day moving average price is $826.05. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Equities research analysts forecast that Eli Lilly and Company will post 16.51 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on LLY shares. Argus increased their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Truist Financial restated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Barclays increased their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Finally, Guggenheim boosted their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $961.76.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 139,490 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $852.29, for a total value of $118,885,932.10. Following the completion of the transaction, the insider now directly owns 97,869,320 shares in the company, valued at $83,413,042,742.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 876,900 shares of company stock valued at $788,605,032 in the last quarter. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.